Childhood and Adolescent Migraine Prevention [CHAMP] Trial: The 3-year Follow-up Survey Results
In this medfyle
Expert commentary by Marcy Yonker, MD, FAHS
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the AHSAM 2020 Virtual Annual Scientific Meeting and presented by:
Scott W. Powers, PhD, ABPP, FAHS
Professor of Pediatrics and CCRF Endowed Chair
Cincinnati Children's Hospital and University of Cincinnati College of Medicine
Wyoming, Ohio
The content is produced by Infomedica, the official reporting partner of ASHAM 2020 Virtual Annual Scientific Meeting. The summary text was drafted by Goldcrest Medical Writing, reviewed by Marco Vercellino, MD, an independent external expert, and approved by Jessica Ailani, MD, FAHS and Mark J. Burish, MD, PhD, the scientific editors of the program.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Marcy Yonker, MD, FAHS
Professor of Clinical Practice, University of Colorado School of Medicine
Director, Pediatric Headache Program, Children's Hospital Colorado
About the Expert
Marcy Yonker, MD, FAHS
Professor of Clinical Practice, University of Colorado School of Medicine
Director, Pediatric Headache Program, Children's Hospital Colorado
Dr. Marcy Yonker is a board certified Pediatric Headache Specialist who has spent the past 20 years in Philadelphia, Phoenix and now Denver treating children with severe headache problems, training headache fellows and participating in clinical research with her many headache friends across the country. She holds the Francescon Endowed Chair in Headache and is a full professor in Clinical Practiceat the University of Colorado School of Medicine and directs the Pediatric Headache Program at Children's Colorado.
References
1. Powers et al. Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine. The New England Journal of Medicine 2017;376:115-124.
2. Oskoui M, Pringsheim T, Billinghurst L et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention. Neurology 2019;93:500-509.
